SAN DIEGO, July 17, 2026 — Mirador Therapeutics, a heavily funded immunology biotech, disclosed its first pipeline program on Thursday, striking a worldwide licensing deal for a drug from Kira Pharmaceuticals that targets the same complement 5a receptor as Amgen’s Tavneos (avacopan). The privately held San Diego company, which has raised over $650 million in venture capital, has been notably secretive about its research until now.

The agreement brings Mirador a clinical-stage asset designed to compete directly in the ANCA-associated vasculitis and other complement-mediated disease markets. Tavneos, originally from ChemoCentryx, was acquired by Amgen in 2022 and generated $421 million in 2025 sales. Mirador’s move signals a serious entry into the space, backed by substantial capital and a broad immunology pipeline still largely undisclosed. Endpoints News first reported the deal.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

WASHINGTON, July 16, 2026 — The death of U.S. Senator Lindsey Graham from an aortic dissection, reported Wednesday, has cast a spotlight on a rare vascular emergency that often presents without prior symptoms. According to a STAT News report, the condition occurs when the inner layer of the body's largest artery tears, allowing blood to split the vessel wall — a fatal event in many cases.

The disorder affects a small fraction of the population and has historically been difficult to predict, leaving a gap in both diagnostic and therapeutic development. While several medtech companies offer stent grafts for emergency repair, there remains no widely adopted screening tool for at‑risk patients. For the biotech sector, the high‑profile event may direct fresh investment attention toward biomarker‑based warning systems and genetic testing for connective‑tissue disorders linked to aortic fragility.

Primary source: STAT News, July 15, 2026.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

The Federal Trade Commission settled a lawsuit against CVS Health’s (CVS) pharmacy benefit manager, Caremark, on Tuesday, resolving charges that the company artificially inflated insulin prices and restricted patient access to the diabetes treatment, according to a report by STAT News. The settlement terms were not immediately disclosed, and CVS did not admit wrongdoing as part of the agreement.

The case marked one of the FTC’s most aggressive actions targeting the opaque rebate systems used by pharmacy benefit managers, which have been under bipartisan scrutiny for their role in driving up list prices for essential therapies. The settlement could pressure other major PBMs to restructure their formulary contracts, potentially reshaping the commercial landscape for insulin manufacturers.

Source: STAT News — FTC settles lawsuit with CVS Caremark over charges it manipulated insulin prices, impeded access (July 14, 2026).

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

OSLO, July 14, 2026 — The U.S. Food and Drug Administration on July 13 released final clinical guidance for psychedelic drug developers and announced a planned public hearing on therapeutic use, providing regulatory clarity to a class approaching potential approvals. The document outlines trial design considerations for MDMA, psilocybin, and related compounds, addressing endpoint selection, safety monitoring, and the integration of psychotherapy in treatment protocols.

The guidance arrives as investor interest in psychedelic-assisted therapies intensifies, with several late-stage programmes targeting post-traumatic stress disorder and major depressive disorder. By scheduling a broader public hearing, the agency signals it is preparing to tackle the distinct regulatory challenges these modalities pose, well before new drug applications are submitted.

Source: Endpoints News — FDA finalizes guidance on psychedelics, plans broader hearing

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

BASEL, July 10, 2026 — Roche (RHHBY) has discontinued development of tominersen, its antisense oligonucleotide for Huntington’s disease, after the Phase 2 GENERATION HD2 study showed no benefit over placebo. The company is also shelving an undisclosed early-stage Huntington’s asset, leaving no clinical-stage HD candidates in its pipeline.

The tominersen program spanned more than a decade and included a high-profile Phase 3 trial that was halted in 2021 due to a safety signal, followed by the redesigned Phase 2 study that now failed on efficacy. The withdrawal eliminates one of the few late-stage ASO approaches for HD, while Ionis Pharmaceuticals (IONS) continues early testing of an alternative allele-selective ASO.

The decision was first reported by Endpoints News.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

Health and Human Services Secretary Robert F. Kennedy Jr. announced on July 8 that the department will draft a new injury table for Covid‑19 vaccines under the Countermeasures Injury Compensation Program (CICP), STAT News reported. The table would list specific conditions presumed to be caused by the vaccines, shifting the burden of proof away from claimants seeking compensation.

Unlike the National Vaccine Injury Compensation Program, which uses a predefined injury table for routine childhood vaccines, the CICP currently lacks such a list for pandemic countermeasures. The move signals a potential structural change in how the government handles vaccine‑related injuries during public health emergencies, a topic that has drawn sharp political scrutiny since the rollout of Covid‑19 shots.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

BOSTON, July 8, 2026 — Vertex Pharmaceuticals (VRTX) said it will acquire endocrinology startup Crinetics for $10 billion, marking the cystic fibrosis leader’s largest push beyond its core franchise. The deal, announced Tuesday, gives Vertex a pipeline of late-stage therapies for rare endocrine disorders.

The move signals Vertex’s ambition to diversify revenue as its CF franchise matures. Crinetics’ lead candidate, an oral ACTH antagonist, is in Phase 3 for Cushing’s disease, with additional programs in congenital adrenal hyperplasia. The deal mirrors large-cap biopharma’s appetite for targeted rare-disease assets with clear regulatory paths.

Reported by Endpoints News.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.

BOSTON — Vertex Pharmaceuticals (VRTX) will acquire San Diego-based Crinetics Pharmaceuticals (CRNX) for $10 billion in cash, the companies announced late Monday. The deal hands Vertex paltusotine, an oral somatostatin receptor agonist in Phase 3 development for acromegaly, a rare endocrine disorder caused by excess growth hormone.

Biopharma M&A remains brisk as large-cap firms deploy cash to fill pipelines facing looming patent cliffs. Paltusotine, if approved, would diversify Vertex beyond its cystic fibrosis franchise into endocrinology. The transaction is expected to close in the second half of 2026.

STAT News first reported the acquisition.

Not financial advice. Content is for educational purposes only. Consult a licensed financial advisor before making investment decisions.